Biotech Values

[rkrw]

I think onxx is cash flow negative but of course that's because they're investing heavily in carfilzomib (and other programs). Nexavar itself throws off a lot of cash which covers a good chunk of their r&d expense.

Anyway, it's the holiday season, you guys should lighten up a little bit.